Is It the Right Time to Issue Guidelines for Treatment of Recalcitrant Dermatophytosis? |

.

                                Profession
                                
Mobile
                                        
                                Speciality
                                
                                Medical Council
                                
                                Registration Number

Is It the Right Time to Issue Guidelines for Treatment of Recalcitrant Dermatophytosis? |

Conferences

eMediNexus Coverage from:

Is It the Right Time to Issue Guidelines for Treatment of Recalcitrant Dermatophytosis?

Dr Abir Saraswat, Lucknow, 21 January 2019
990 Views

#Dermatology

The tinea epidemic is more than 5 years old.Difficulties in treatment arises due to:o Rapidly progressive disease that spreads easily amongst contactso Unusual, highly symptomatic manifestationso Poor response to recommend treatmentso Repeated episodes in spite of apparently successful treatment.The need for new guidelines is evident; however, guidelines are only as good as; clear definition of the clinical problem in all its aspects, the rigor of process followed for the...

To read the complete article ,

create a free account.

Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies

Create Account

Already registered?

Recommended CME's

Good Pharmacy Practices:Certification Course Modules

Pharmacists

Management of Fungal Infections

Dermatology

A comprehensive course on dengue-screening, diagnosis and management

Infectious Diseases

Allergic Rhinitis: Approach to Day to Day Management

Allergy & Clinical Immumology

NUTRITIONAL STRATEGY IN DIABETES MANAGEMENT DURING COVID-19

Diabetes & Endocrinology

Topical Antibiotic in the Management of Skin and Soft Tissue Infection

Dermatology

advertisment

advertisment

advertisment

Trending Articles

Conferences

eMediNexus Coverage from: AOICON 2019

Is It the Right Time to Issue Guidelines for Treatment of Recalcitrant Dermatophytosis?

Dr Abir Saraswat, Lucknow, 21 January 2019
#Dermatology

news Image

The tinea epidemic is more than 5 years old.
Difficulties in treatment arises due to:

o Rapidly progressive disease that spreads easily amongst contacts

o Unusual, highly symptomatic manifestations

o Poor response to recommend treatments

o Repeated episodes in spite of apparently successful treatment.

The need for new guidelines is evident; however, guidelines are only as good as; clear definition of the clinical problem in all its aspects, the rigor of process followed for their generation and the quality of data that is used as their basis.
Issuing different guidelines for a poor drug quality driven epidemic would be pointless and may be even dangerous.
Guideline development in India was undergoing transition toward adoption of systematic, transparent and evidence-based approaches but several barriers in the form of attitudes towards use of evidence, lack of methodological capacity, inadequate governance structure and funding exist.
Treatment guidelines in the absence of MIC breakpoints:

o There are no defined criteria for labeling dermatophyte strains sensitive or resistant

o Clinical-lab correlation for antifungal sensitivity studies remains relatively poor

o A recent expert consensus recommended terbinafine or itraconazole for the initial treatment of tinea corporis.